MedTrace Logo

Post Marketing Surveillance of Synflorix Vaccine Safety Among Infants in Korea

NCT01248988 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 622

Last updated 2017-01-13

No results posted yet for this study

Summary

The purpose of this study is to collect safety information following routine vaccination with Synflorix™ among infants in Korea.

Conditions

  • Infections, Streptococcal

Interventions

OTHER

Synflorix™ Data collection

Safety monitoring: recording of adverse events during using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
6 Weeks
Max Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01248988 on ClinicalTrials.gov